ChromaDex to Present at the 3rd Annual NAD+ Summit
24 janv. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today it will...
ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary
23 janv. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it...
Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)
22 janv. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the...
ChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in Singapore
08 janv. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced the...
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
14 déc. 2017 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important...
Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research
08 déc. 2017 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that...
The promoting mechanism of TRU NIAGEN™ to be featured at the American Academy of Anti-Aging Medicine World Congress
04 déc. 2017 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today it...
ChromaDex to Present at the 10th Annual LD Micro Main Event
29 nov. 2017 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that...
ChromaDex Reports Third Quarter 2017 Financial Results
09 nov. 2017 16h05 HE
|
ChromaDex Corporation
- Company Reports Third Quarter 2017 Revenue of $6.1 Million, Up 55% Compared to Last Year -- Continued Progress on Building a Consumer Products Platform Around TRU NIAGEN™- IRVINE, Calif., Nov. 09,...
ChromaDex Announces $23 million Private Placement of Common Stock
06 nov. 2017 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that...